Home › Cancer types › Glioblastoma

Just diagnosed with glioblastoma?

By the Cancer Clues team · Last updated 1 November 2026 · How we grade treatments

The honest numbers — with the context that matters

Statistics describe groups, never one person — and in glioblastoma the gap between group averages and individual stories is unusually wide. Age, how much surgeons can safely remove, and a tumor marker called MGMT all shift the picture.

• Roughly 12,000–14,000 US diagnoses a year (estimate — about half of all malignant brain tumors); median age 66 [1][2].
• Across everyone diagnosed — including people too unwell for full treatment — median survival is around 8 months and five-year survival about 7% [2].
• With the full standard path in trials: median survival was 14.6 months with surgery + radiation + temozolomide [4], and 20.9 months when the Optune device was added — with roughly 13% of patients in that trial alive at five years (as reported in trial coverage) [5].
• There is no screening test for brain tumors; nobody could have caught this early. If guilt about “missed signs” is eating at you or your family: the medicine says there was no test to take [1].

What's actually proven

• The standard path (“Stupp protocol”): maximal safe surgery, then six weeks of radiation with daily temozolomide chemotherapy, then monthly maintenance temozolomide. This is the backbone worldwide [3][4].
• Optune (tumor-treating fields): a wearable device of scalp electrodes creating electric fields that disturb tumor-cell division. FDA-approved with maintenance chemo; added about five months of median survival in its randomized trial. The honest trade-off: it should be worn ~18+ hours a day, shaved-head, with skin irritation the main side effect — some people find that worth it, some don't [5].
• At recurrence: options exist (bevacizumab, lomustine, re-operation, trials), and honesty requires saying they help symptoms and time more than survival [3].
• Molecular testing matters: MGMT status predicts chemo benefit; IDH status defines the diagnosis itself. Ask for both results by name [3].

Stage-by-stage depth: the National Cancer Institute's patient guide [3] and the NCCN patient guideline for gliomas [6].

What people ask about (from our graded library)

GBM forums are the most intense corner of alternative-medicine internet — desperation deserves honesty, not marketing:

• Ketogenic diet — most of the actual human research was done in glioma: feasible, and the one randomized trial found no delay in tumor growth. Graded Unknown; risky if you're losing weight.
• Cannabis & CBD — the only completed placebo-controlled cannabinoid cancer trial was in recurrent GBM (27 patients, safety-focused); the definitive trial is running now. Graded Unknown for treating the tumor.
• High-dose IV vitamin C — a 55-patient GBM study against historical comparisons points cautiously the right way; graded Promising overall, unproven in GBM, trial-setting only.
• Fenbendazole — huge in GBM groups; zero human trials, documented liver injuries. Read the page before deciding anything.

Does the hospital matter? Here, more than almost anywhere

Observational studies consistently find longer survival when GBM is treated at high-volume, academic centers — a Finnish nationwide study found median survival of 9.3 vs 7.8 months between high- and low-volume hospitals, and US registry analyses point the same way [7]. The deeper reasons: specialized neurosurgeons safely remove more tumor, molecular testing is faster and fuller, and clinical trials — realistically the only route to much better outcomes — live almost exclusively at major centers (the international GBM AGILE platform trial, for example, tests several new drugs at once [8]). Our practical advice, offered gently but firmly: get a second opinion from a dedicated neuro-oncology center in week one, even if treatment then happens closer to home. That is exactly what our Sprint arranges.

What's new (and what isn't)

• A caution about headlines: the celebrated 2024 “brain-cancer pill” (vorasidenib) is for grade 2 IDH-mutant glioma — by definition a different disease from glioblastoma. It does not apply to GBM, whatever a well-meaning relative read [9].
• CAR-T immune-cell therapy: in 2024, engineered immune cells caused dramatic tumor shrinkage within days in the first recurrent-GBM patients — mostly temporary, and the trials are tiny and ongoing. Real scientific hope, not yet a therapy [10].
• Platform trials like GBM AGILE test multiple candidates simultaneously — asking “which trials fit me, here or elsewhere?” is the single highest-value question in this disease [8].

Questions for your neuro-oncology team (bring this list)

1. How much of the tumor could be removed, and by a surgeon doing how many of these per year?
2. What are my MGMT and IDH results, and what do they change?
3. Is Optune on the table — and can you connect me with a patient who uses it?
4. Which clinical trials fit my situation, at this center or anywhere? (Ask about GBM AGILE.)
5. Can my case be reviewed by a dedicated neuro-oncology tumor board this week?

Common questions